Payment overview · 2025
General Payments
$1,581.23
68 reported records · 20 companies
Healthcare provider profile · identity verified
Eduardo Torres, MD
Allopathic & Osteopathic Physicians|Family Medicine · WINTER HAVEN, FL · NPI 1679553606
Verified facts
What the public records show
CMS Open Payments records show Eduardo Torres, MD received $1,581.23 in general payments during 2025 across 68 reported records.
AstraZeneca Pharmaceuticals LP accounted for 19.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Rexulti, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $307.81 | 19.5% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $198.86 | 12.6% | 11 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $150.59 | 9.5% | 5 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $135.51 | 8.6% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $119.27 | 7.5% | 2 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $95.25 | 6.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $83.64 | 5.3% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $77.23 | 4.9% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $62.95 | 4.0% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $59.93 | 3.8% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $56.48 | 3.6% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $36.19 | 2.3% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.78 | 2.3% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.43 | 2.0% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.71 | 1.8% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $26.44 | 1.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $22.50 | 1.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.21 | 1.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.77 | 1.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.68 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,581.23 | 68 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $218.29 | 6 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $150.59 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $143.64 | 8 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $135.51 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $130.75 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $119.27 | 2 | 2025 |
Source payment records
|
|||||
| Mavenclad Normalized: mavenclad |
Drug | EMD Serono, Inc. | $95.25 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $79.70 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $77.23 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $62.77 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $56.48 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $48.50 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $45.17 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $45.17 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $40.46 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $40.46 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $40.46 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $36.19 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $35.78 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $31.43 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.43 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $30.36 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $27.71 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $26.44 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $25.84 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.22 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $20.87 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $20.21 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $20.21 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 29 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 71 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 39 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 79 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 72 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 98 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 57 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
39 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
47 | 18 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
79 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
29 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
26 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
79 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
72 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
98 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
57 | 13 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
71 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 928 | 297 |
| Amlodipine Besylate | Amlodipine Besylate | 486 | 158 |
| Levothyroxine Sodium | Levothyroxine Sodium | 482 | 149 |
| Losartan Potassium | Losartan Potassium | 476 | 146 |
| Lisinopril | Lisinopril | 434 | 132 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 424 | 137 |
| Gabapentin | Gabapentin | 352 | 105 |
| Metformin Hcl | Metformin Hcl | 336 | 107 |
| Omeprazole | Omeprazole | 332 | 101 |
| Pantoprazole Sodium | Pantoprazole Sodium | 289 | 99 |
| Hydrochlorothiazide | Hydrochlorothiazide | 274 | 86 |
| Simvastatin | Simvastatin | 274 | 80 |
| Tamsulosin Hcl | Tamsulosin Hcl | 273 | 100 |
| Metoprolol Succinate | Metoprolol Succinate | 263 | 88 |
| Trazodone Hcl | Trazodone Hcl | 214 | 74 |
| Metoprolol Tartrate | Metoprolol Tartrate | 209 | 63 |
| Furosemide | Furosemide | 206 | 66 |
| Carvedilol | Carvedilol | 177 | 57 |
| Meloxicam | Meloxicam | 174 | 56 |
| Potassium Chloride | Potassium Chloride | 169 | 57 |
| Montelukast Sodium | Montelukast Sodium | 167 | 56 |
| Sertraline Hcl | Sertraline Hcl | 153 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 133 | 43 |
| Ezetimibe | Ezetimibe | 129 | 43 |
| Alprazolam | Alprazolam | 128 | 45 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 127 | 67 |
| Clopidogrel | Clopidogrel Bisulfate | 119 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 114 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 113 | 39 |
| Glimepiride | Glimepiride | 102 | 37 |
| Glipizide Er | Glipizide | 101 | 25 |
| Ozempic | Semaglutide | 98 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 97 | 30 |
| Famotidine | Famotidine | 97 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 95 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 92 | 42 |
| Metformin Hcl Er | Metformin Hcl | 91 | 34 |
| Allopurinol | Allopurinol | 87 | 27 |
| Bupropion Xl | Bupropion Hcl | 87 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 85 | 24 |
| Jardiance | Empagliflozin | 79 | 18 |
| Chlorthalidone | Chlorthalidone | 78 | 25 |
| Alendronate Sodium | Alendronate Sodium | 77 | 30 |
| Glipizide | Glipizide | 77 | 26 |
| Myrbetriq | Mirabegron | 74 | 15 |
| Mounjaro | Tirzepatide | 72 | 13 |
| Eliquis | Apixaban | 71 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 69 | 27 |
| Clonidine Hcl | Clonidine Hcl | 68 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 67 | 19 |
| Spironolactone | Spironolactone | 65 | 20 |
| Donepezil Hcl | Donepezil Hcl | 59 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 59 | 16 |
| Rybelsus | Semaglutide | 57 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 57 | 21 |
| Fenofibrate | Fenofibrate | 56 | 17 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 52 | 16 |
| Methylprednisolone | Methylprednisolone | 52 | 47 |
| Clonazepam | Clonazepam | 51 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 51 | 22 |
| Prednisone | Prednisone | 48 | 33 |
| Finasteride | Finasteride | 47 | 17 |
| Lovastatin | Lovastatin | 47 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 47 | 18 |
| Irbesartan | Irbesartan | 46 | 13 |
| Pregabalin | Pregabalin | 45 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 15 |
| Memantine Hcl | Memantine Hcl | 44 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 44 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 43 | 16 |
| Atenolol | Atenolol | 42 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | 14 |
| Azithromycin | Azithromycin | 41 | 40 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 40 | 13 |
| Baclofen | Baclofen | 40 | 18 |
| Farxiga | Dapagliflozin Propanediol | 39 | 14 |
| Mirtazapine | Mirtazapine | 39 | 13 |
| Trulicity | Dulaglutide | 39 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 29 |
| Lorazepam | Lorazepam | 37 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 34 |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | 15 |
| Temazepam | Temazepam | 34 | suppressed |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Jantoven | Warfarin Sodium | 32 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | 11 |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 13 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 29 | 29 |
| Primidone | Primidone | 29 | 12 |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Eszopiclone | Eszopiclone | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 26 | 20 |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Celecoxib | Celecoxib | 25 | 13 |
| Nitroglycerin | Nitroglycerin | 25 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 15 |
| Topiramate | Topiramate | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | 11 |
| Bumetanide | Bumetanide | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 21 |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Rexulti | Brexpiprazole | 21 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 21 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 20 |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 17 |
| Icosapent Ethyl | Icosapent Ethyl | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 16 |
| Acyclovir | Acyclovir | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 18 | 13 |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Cholestyramine Light | Cholestyramine | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 16 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 16 | 16 |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 13 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Novolog | Insulin Aspart | 13 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 11 | suppressed |
| Savella | Milnacipran Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,581.23 · 68 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FARXIGA, FREESTYLE LIBRE, GARDASIL 9, JARDIANCE, JATENZO, LEQVIO, MOUNJARO, Mavenclad, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, Symbravo, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error